Literature DB >> 3155647

Promoting effect of nicotinamide on the development of renal tubular cell tumors in rats initiated with diethylnitrosamine.

M R Rosenberg, D L Novicki, R L Jirtle, A Novotny, G Michalopoulos.   

Abstract

Nicotinamide administered in the drinking water of male Fischer 344 rats increased the number of renal tubular cell tumors of rats treated with an i.p. injection of diethylnitrosamine (DEN) (25-mg/kg body weight). The incidence of kidneys with tumors in rats treated with DEN alone was 5%. In rats which received DEN and then were promoted with either 30 or 6.7 mM nicotinamide in their drinking water, the incidence of kidneys with tumors rose to 59 and 28%, respectively. Rats which were on 30 mM nicotinamide but did not receive DEN had no kidney tumors present. These results show that nicotinamide promoted DEN-induced renal tubular cell tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3155647

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  High dietary niacin may increase prostaglandin formation but does not increase tumor formation in ApcMin/+ mice.

Authors:  Alan M Kwong; Brigette L Tippin; Alicia M Materi; Virgilio S Buslon; Samuel W French; Henry J Lin
Journal:  Nutr Cancer       Date:  2011-07-20       Impact factor: 2.900

2.  Role of nicotinamide in DNA damage, mutagenesis, and DNA repair.

Authors:  Devita Surjana; Gary M Halliday; Diona L Damian
Journal:  J Nucleic Acids       Date:  2010-07-25

3.  Preventive effect of 3-aminobenzamide on the reduction of NAD levels in rat liver following administration of diethylnitrosamine.

Authors:  K Uchida; S Takahashi; K Fujiwara; K Ueda; D Nakae; Y Emi; M Tsutsumi; K Shiraiwa; T Ohnishi; Y Konishi
Journal:  Jpn J Cancer Res       Date:  1988-10

Review 4.  The Role of Nicotinamide in Cancer Chemoprevention and Therapy.

Authors:  Ilias P Nikas; Stavroula A Paschou; Han Suk Ryu
Journal:  Biomolecules       Date:  2020-03-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.